{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:44:31Z","timestamp":1769730271162,"version":"3.49.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Wilms tumor 1 (WT1) is a promising target antigen for cancer immunotherapy. However, WT1 protein expression and its clinical correlation in multiple myeloma (MM) patients are still limited. We, therefore, investigated WT1 expression in 142 bone marrow and plasmacytoma samples of MM patients at different stages of the disease by immunohistochemistry. The correlations between WT1 expression and clinical parameters or treatment outcomes were evaluated. The overall positive rate of WT1 expression was 91.5%; this high prevalence was found in both bone marrow and plasmacytoma samples, regardless of the disease status. Cytoplasmic WT1 expression was correlated with high serum free light chain ratio at presentation. However, no significant association between WT1 expression and treatment outcome was observed. This study confirms the high prevalence of WT1 expression in an Asian cohort of MM, encouraging the development of immunotherapy targeting WT1 in MM patients, particularly in those with extramedullary plasmacytoma or relapsed disease.<\/jats:p>","DOI":"10.3389\/pore.2023.1610844","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T04:11:20Z","timestamp":1674533480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["High prevalence of Wilms tumor 1 expression in multiple myeloma and plasmacytoma: A cohort of 142 Asian patients\u2019 samples"],"prefix":"10.3389","volume":"29","author":[{"given":"Ployploen","family":"Phikulsod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanya","family":"Sukpanichnant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chutima","family":"Kunacheewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaweesak","family":"Chieochansin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pa-Thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-a","article-title":"Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus","volume":"60","author":"Call","year":"1990","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.7534\/j.issn.1009-2137.2014.05.005","article-title":"WT1 gene expression difference in leukemia and non-leukemia and its clinical significance","volume":"22","author":"Liu","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1038\/srep08924","article-title":"Wilms\u2019 tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis","volume":"5","author":"Qiwei","year":"2015","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.acthis.2012.04.006","article-title":"Immunohistochemical expression of Wilms\u2019 tumor protein (WT1) in developing human epithelial and mesenchymal tissues","volume":"115","author":"Parenti","year":"2013","journal-title":"Acta Histochem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.36401\/JIPO-20-12","article-title":"Wilms\u2019 tumor 1 (WT1): The vaccine for cancer","volume":"3","author":"Hein","year":"2020","journal-title":"J Immunother Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-risk multiple myeloma: how to treat at diagnosis and relapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: Challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1179\/102453310X12583347009496","article-title":"Expression of WT1 gene in multiple myeloma patients at diagnosis: Is WT1 gene expression a useful marker in multiple myeloma?","volume":"15","author":"Saatci","year":"2010","journal-title":"Hematol Amst Neth"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-04-0825","article-title":"Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes","volume":"10","author":"Azuma","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1182\/blood-2012-06-435040","article-title":"WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions","volume":"121","author":"Tyler","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1016\/j.clml.2017.07.164","article-title":"Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (pts) with high-risk (HR) multiple myeloma (MM)","volume":"17","author":"Koehne","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/BF02983998","article-title":"Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma","volume":"86","author":"Tsuboi","year":"2007","journal-title":"Int J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.7534\/j.issn.1009-2137.2015.03.026","article-title":"Correlation of WT1 and VEGF expression with angiogenesis in bone marrow biopsies of multiple myeloma patients","volume":"23","author":"Li","year":"2015","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ajh.25579","article-title":"Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients","volume":"94","author":"Avivi","year":"2019","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/PAI.0b013e318187dd26","article-title":"Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma","volume":"17","author":"Tsuta","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"B19","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/biomedicines10040912","article-title":"Evaluating established roles, future perspectives and methodological heterogeneity for Wilms\u2019 tumor 1 (WT1) antigen detection in adult renal cell carcinoma, using a novel N-terminus targeted antibody (clone WT49)","volume":"10","author":"Novacescu","year":"2022","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12882-018-0962-x","article-title":"Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma","volume":"19","author":"Yadav","year":"2018","journal-title":"BMC Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: Powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/hmg\/ddh040","article-title":"The Wilms\u2019 tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes","volume":"13","author":"Niksic","year":"2004","journal-title":"Hum Mol Genet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20131587","article-title":"Mechanisms of transcriptional regulation by WT1 (Wilms\u2019 tumour 1)","volume":"461","author":"Toska","year":"2014","journal-title":"Biochem J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/sj.onc.1201747","article-title":"Activation of the wt1 Wilms' tumor suppressor gene by NF-kappaB","volume":"16","author":"Dehbi","year":"1998","journal-title":"Oncogene"},{"key":"B28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: Basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int J Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1172\/JCI44165","article-title":"Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models","volume":"120","author":"Vicent","year":"2010","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12967-020-02384-y","article-title":"WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target","volume":"18","author":"Zhou","year":"2020","journal-title":"J Transl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.1038\/sj.onc.1207609","article-title":"Transcriptional activation of c-myc proto-oncogene by WT1 protein","volume":"23","author":"Han","year":"2004","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1073\/pnas.94.15.8132","article-title":"Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer","volume":"94","author":"Silberstein","year":"1997","journal-title":"Proc Natl Acad Sci"},{"key":"B33","first-page":"1691","article-title":"Immunohistochemical detection of WT1 protein in endometrial cancer","volume":"29","author":"Ohno","year":"2009","journal-title":"Anticancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/01.MP.0000028646.03760.6B","article-title":"The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors","volume":"15","author":"Carpentieri","year":"2002","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1002\/j.1460-2075.1996.tb00945.x","article-title":"Regulation of WT1 by phosphorylation: Inhibition of DNA binding, alteration of transcriptional activity and cellular translocation","volume":"15","author":"Ye","year":"1996","journal-title":"EMBO J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood-2006-08-042747","article-title":"Targeting PKC in multiple myeloma: In vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)","volume":"109","author":"Podar","year":"2007","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1046\/j.1365-2141.2003.04368.x","article-title":"Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis","volume":"121","author":"Ni","year":"2003","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"31930","DOI":"10.1074\/jbc.M602668200","article-title":"The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the alpha4integrin gene","volume":"281","author":"Kirschner","year":"2006","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1093\/hmg\/ddt358","article-title":"WT1 regulates the expression of inhibitory chemokines during heart development","volume":"22","author":"Velecela","year":"2013","journal-title":"Hum Mol Genet"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1610844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T04:11:25Z","timestamp":1674533485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2023.1610844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":39,"alternative-id":["10.3389\/pore.2023.1610844"],"URL":"https:\/\/doi.org\/10.3389\/pore.2023.1610844","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"article-number":"1610844"}}